3,752 reports of this reaction
2.1% of all FINGOLIMOD HCL reports
#7 most reported adverse reaction
HYPOAESTHESIA is the #7 most commonly reported adverse reaction for FINGOLIMOD HCL, manufactured by Novartis Pharmaceuticals Corporation. There are 3,752 FDA adverse event reports linking FINGOLIMOD HCL to HYPOAESTHESIA. This represents approximately 2.1% of all 175,367 adverse event reports for this drug.
Patients taking FINGOLIMOD HCL who experience hypoaesthesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOAESTHESIA is a less commonly reported adverse event for FINGOLIMOD HCL, but still significant enough to appear in the safety profile.
In addition to hypoaesthesia, the following adverse reactions have been reported for FINGOLIMOD HCL:
The following drugs have also been linked to hypoaesthesia in FDA adverse event reports:
HYPOAESTHESIA has been reported as an adverse event in 3,752 FDA reports for FINGOLIMOD HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOAESTHESIA accounts for approximately 2.1% of all adverse event reports for FINGOLIMOD HCL, making it a notable side effect.
If you experience hypoaesthesia while taking FINGOLIMOD HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.